Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.51 |
| ▸ | CDC25B | P30305 | 1/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.42 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DTYMK | P23919 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL670410 | 0.88 | HCAR3 (0.55) | MAPTHCAR3CDC25BAKR1C2AKR1C1 | |
| SCHEMBL8900476 | 0.85 | HCAR3 (0.59) | MAPTHCAR3CDC25BAKR1C2HTT | |
| SCHEMBL29109409 | 0.85 | MAPT (0.59) | MAPTHCAR3CDC25BAKR1C2AKR1C1 | |
| SCHEMBL28544472 | 0.85 | SMN1; SMN2 (0.52) | MAPTCDC25BAKR1C2AKR1C1HTT | |
| SCHEMBL13195393 | 0.82 | HCAR3 (0.39) | MAPTHCAR3CDC25BAKR1C2AKR1C1 | |
| SCHEMBL23418074 | 0.80 | HCAR3 (0.47) | MAPTHCAR3CDC25BHTTESPL1 | |
| SCHEMBL670578 | 0.80 | DTYMK (0.46) | MAPTAKR1C2AKR1C1HTTESPL1 | |
| SCHEMBL5167381 | 0.79 | SMN1; SMN2 (0.52) | MAPTCDC25BAKR1C2AKR1C1HTT | |
| SCHEMBL2240615 | 0.79 | TSHR (0.51) | HCAR3CDC25BAKR1C2AKR1C1ESPL1 | |
| SCHEMBL11951407 | 0.78 | HTT (0.49) | MAPTHCAR3CDC25BAKR1C2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606036-B1 | 2-ANILINOBENZIMIDAZOLE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-8759537-B2 | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| EP-2649051-A1 | 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2606036-A1 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120214786-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076673-A1 | 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012022793-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | MAPT 4336/4885HCAR3 228/4885CDC25B 1778/4885 |
| US-20120214786-A1 | NEW COMPOUNDS | PTGER1, PTGS1, PTGES | MAPT 4286/4885HCAR3 373/4885CDC25B 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.